Zamtocabtagene Autoleucel (Zamto-Cel), a Tandem CD20-CD19 Directed CAR-T cell Therapy As Second-Line Treatment for relapsed/refractory Large B-cell Lymphoma: Primary analysis of the Randomized, Pivotal DALY 2-EU Study

Transplantation and Cellular Therapy 2026

View at publisher
Authors: Peter Borchmann, Tom van Meerten, Pierre Bories, Peter Dreger, László Gopcsa, Pim G. N. J. Mutsaers, Matthias Edinger, Lajos Gergely, Bastian von Tresckow, Peter Neumeister, Normann Steiner, Ulrich Jäger
+16 more Ana Triguero Moreno, Laimonas Griškevičius, Gloria Iacoboni, François Lemonnier, Jaap A. van Doesum, Nirav Niranjan Shah, Rimas J. Orentas, Birte Friedrichs, Stefan Miltenyi, Toon Overstijns, Iris Bürger, Gregor Zadoyan, Corinne Brillant, Pearl van Heteren, Silke Holtkamp, Peter Vandenberghe
DOI: 10.1016/j.jtct.2025.12.096
Cited by: 0

Fields of Study & Subjects

CAR-T cell therapy research Lymphoma Diagnosis and Treatment T-cell and B-cell Immunology

Publication details

Journal / source
Transplantation and Cellular Therapy
Volume
32
Issue
2
Pages
S64–S64
Publication date
1 February 2026
Language
EN